Fate Therapeutics Inc.’s filing revealed that its Chief Financial Officer Dulac Edward J III unloaded Company’s shares for reported $13210.0 on Aug 18. In the deal valued at $2.80 per share,4,718 shares were sold. As a result of this transaction, Dulac Edward J III now holds 119,570 shares worth roughly $ 0.32 million.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Then, Xu Yuan sold 632 shares, generating $2,345 in total proceeds. Upon selling the shares at $3.71, the Director now owns 9,302 shares.
Before that, Dulac Edward J III sold 5,182 shares. Fate Therapeutics Inc. shares valued at $25,029 were divested by the Chief Financial Officer at a price of $4.83 per share. As a result of the transaction, Dulac Edward J III now holds 124,288 shares, worth roughly $0.34 million.
PT values the company’s stock at a premium of 54.83 to its Tuesday closing price.
Price Performance Review of FATE
On Tuesday, Fate Therapeutics Inc. [NASDAQ:FATE] saw its stock fall -3.56% to $2.71. On the same session, the stock had its day’s lowest price of $2.67, but rose to a high of $2.99. Over the last five days, the stock has gained 1.88%. Fate Therapeutics Inc. shares have fallen nearly -73.14% since the year began. Nevertheless, the stocks have fallen -89.97% over the past one year. While a 52-week high of $29.42 was reached on 01/05/23, a 52-week low of $2.49 was recorded on 08/25/23. SMA at 50 days reached $3.84, while 200 days put it at $6.98. A total of 3.02 million shares were traded, compared to the trading of 2.96 million shares in the previous session.
Levels Of Support And Resistance For FATE Stock
The 24-hour chart illustrates a support level at 2.59, which if violated will result in even more drops to 2.47. On the upside, there is a resistance level at 2.91. A further resistance level may holdings at 3.11. The Relative Strength Index (RSI) on the 14-day chart is 34.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 56.57%. Stochastics %K at 52.66% indicates the stock is a holding.
How much short interest is there in Fate Therapeutics Inc.?
A steep rise in short interest was recorded in Fate Therapeutics Inc. stocks on Aug 14, 2023, growing by 2.62 million shares to a total of 28.29 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 25.67 million shares. There was a rise of 9.26%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 36.79% of the overall stock float, the days-to-cover ratio (short ratio) rose to 13.89.
Fate Therapeutics Inc. [FATE] – Who Are The Largest Shareholders?
In filings from Redmile Group LLC, it is revealed that the company now owns 13,124,427 shares, or roughly 13.34% of the outstanding FATE shares. In other words, the investor’s shares have risen by 167,205 from its previous 13-F filing of 12957222.0. Additionally, The Vanguard Group, Inc. increased 7.91% of its stake after which the total value it holdings stand at $47,850,605, while SSgA Funds Management, Inc. reduced -30.45% of its stake to hold $42.6 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 556,022 shares of Fate Therapeutics Inc., while Bellevue Asset Management AG bought 0 shares. At present, D. E. Shaw & Co. LP is holding 4,599,439 shares valued at $19.0 million. Federated MDTA LLC owned 2,469,299 shares of the company at the time of its most recent 13F filing, worth $10.2 million.
According to FactSet, Fate Therapeutics Inc.’s share price will average $7.19 in the next year, based on opinions of analysts polled by the firm. This is up nearly 113.52 percent from its previous closing price of $2.81. Analysts expect Fate Therapeutics Inc. stock to reach the higher price of $16.00, while the lowest price estimate is $4.00. However, 22 analysts have rated FATE stock as a Hold in their predictions for 2023.